Abstract Library

#3126 The potential role of circulating DNA in the management of neuroendocrine tumors: NET Sanguis study

Introduction: Pancreatic neuroendocrine tumors (PNETs) have variable biology, with no validated biomarkers to predict behaviour or treatment response. Circulating tumoral DNA (ctDNA) has been utilised in other cancers as a biomarker for mutation detection, drug target identification and direct change of therapy. ctDNA has been detected in patients with PNETs: its utility as a biomarker in the disease course of PNET patients has not been assessed.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Michael M

Authors: Michael M, Segelov E, Chan D, Wyld D, Price T,

Keywords: pancreatic neuroendocrine tumor, biomarker, circulating DNA,

#1920 Optimising Followup after Complete Surgical Resection of Gastrointestinal Neuroendocrine Tumours- A Delphi Process to Produce Expert Consensus in an Area Lacking Clinical Evidence

Introduction: Optimal follow-up for completely resected GI-NETS has not been well defined, with heterogeneity in awareness and application of existing guidelines.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Moody L, Segelov E, Chan D, Carsley S, Strosberg J,

Keywords: RAM,NET,

#1719 Escalated Dose Somatostatin Analogues for Anti-Proliferative Effect in Gastroenteropancreatic Neuroendocrine Tumours (GEPNETS): A Systematic Review

Introduction: Somatostatin analogues (SSAs) are the cornerstone of systemic therapy for well-differentiated GEPNETs. Dose escalation of SSAs is often trialled in clinical practice, but small studies have yielded mixed results.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Chan D, Ferone D, Segelov E, Albertelli M, Singh S,

Keywords: Escalated dose, octreotide, lanreotide, SSA,

#1366 CommNETS: Formation of an International Commonwealth Countries NET Partnership

Introduction: Neuroendocrine tumours (NETs) care is challenging in Canada, Australia and New Zealand due to small populations in large geographical space, limited drug funding, and lack of NET awareness. There is a need for collaboration to focus research and improve care and outcomes for NET patients in these nations with similar health systems.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Singh S

Authors: Singh S, Lawrence B, Chan D, Pavlakis N, Segelov E,

Keywords: research, society,

#1358 Identifying and Prioritising Gaps in Neuroendocrine Tumour Research - Results of the Delphi Consensus Project of the Commonwealth Neuroendocrine Tumour Research Collaboration (CommNETS)

Introduction: The newly formed CommNETS group used the robust Delphi methodology with broad stakeholder engagement to form a strategic research agenda.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Segelov E

Authors: Segelov E, Chan D, Harris-Roxas B, Lawrence B, Pavlakis N,

Keywords: research, gaps, priorities, Delphi ,